These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 27598348)

  • 41. Sickle cell disease and stroke.
    Verduzco LA; Nathan DG
    Blood; 2009 Dec; 114(25):5117-25. PubMed ID: 19797523
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
    Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL;
    Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ten-year review of hospital admissions among children with sickle cell disease in Kuwait.
    Akar NA; Adekile A
    Med Princ Pract; 2008; 17(5):404-8. PubMed ID: 18685282
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sickle cell disease: progress towards combination drug therapy.
    Pace BS; Starlard-Davenport A; Kutlar A
    Br J Haematol; 2021 Jul; 194(2):240-251. PubMed ID: 33471938
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advances in the Treatment of Sickle Cell Disease.
    Kapoor S; Little JA; Pecker LH
    Mayo Clin Proc; 2018 Dec; 93(12):1810-1824. PubMed ID: 30414734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 47. Immunological role of CD4
    ElAlfy MS; Adly AAM; Ebeid FSE; Eissa DS; Ismail EAR; Mohammed YH; Ahmed ME; Saad AS
    Immunol Res; 2018 Aug; 66(4):480-490. PubMed ID: 29926339
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.
    Manwani D; Frenette PS
    Hematology Am Soc Hematol Educ Program; 2013; 2013():362-9. PubMed ID: 24319205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.
    Keikhaei B; Yousefi H; Bahadoram M
    Glob J Health Sci; 2015 Aug; 8(3):252-6. PubMed ID: 26493428
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical management of adult sickle-cell disease.
    Bartolucci P; Galactéros F
    Curr Opin Hematol; 2012 May; 19(3):149-55. PubMed ID: 22357165
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Orbital subperiosteal hematoma in child with sickle cell thalassemia. A case report].
    Douira-Khomsi W; Jarraya M; Ben Hassine L; Louati H; Chebbi A; Lahmar L; Bouguila H; Bellagha I
    Arch Pediatr; 2010 Aug; 17(8):1174-7. PubMed ID: 20452192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease.
    Wang WC
    Exp Biol Med (Maywood); 2016 Apr; 241(7):730-6. PubMed ID: 27026724
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Leg ulcer induced by hydroxycarbamide in sickle cell disease: What is the therapeutic impact?
    Soya E; Makowski C; Blaise S
    Int Wound J; 2019 Aug; 16(4):897-902. PubMed ID: 30916480
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disease-Modifying Therapies for Sickle Cell Disease-An Overview.
    Peddinti R
    Pediatr Ann; 2024 Feb; 53(2):e52-e55. PubMed ID: 38302121
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease.
    Ansari J; Moufarrej YE; Pawlinski R; Gavins FNE
    Expert Rev Hematol; 2018 Jan; 11(1):45-55. PubMed ID: 29207881
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Managing acute chest syndrome of sickle cell disease in an African setting.
    Fawibe AE
    Trans R Soc Trop Med Hyg; 2008 Jun; 102(6):526-31. PubMed ID: 18455745
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease.
    Puffer E; Schatz J; Roberts CW
    Child Neuropsychol; 2007 Mar; 13(2):142-54. PubMed ID: 17364571
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
    Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effect of hydroxyurea on hemoglobin S].
    Torres AF; Eberle SE; Sciuccati G; Bonduel M
    Medicina (B Aires); 2003; 63(2):140-2. PubMed ID: 12793083
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary and Secondary Stroke Prevention in Children With Sickle Cell Disease.
    Mack AK; Thompson AA
    J Pediatr Health Care; 2017; 31(2):145-154. PubMed ID: 27423528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.